Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
9
|
pubmed:dateCreated |
1994-12-8
|
pubmed:abstractText |
A cisplatin (cis-diamminedichloroplatinum(II); CDDP)-resistant HeLa cell line (HeLa/CDDP cells), which showed more than 8-fold resistance to CDDP compared to the parent cells, was newly established for this study. HeLa/CDDP cells accumulated 50% less platinum than the parent cells. There was no difference in intracellular glutathione (GSH) content between the parent and HeLa/CDDP cells. The dose modification factor by DL-buthionine-S,R-sulfoximine (BSO) pretreatment was similar in both cell lines. HeLa/CDDP cells had cross-resistance to diammine(1,1-cyclobutanedicarboxylato)platinum(II) (CBDCA), (cis-diammine(glycolato)platinum (254-S), but not to (-)-(R)-2-aminomethylpyrrolidine(1,1-cyclobutanedicarboxylato++ +)platinum(II) (DWA2114R), adriamycin, or VP-16. HeLa/CDDP cells showed a collateral sensitivity to 7-ethyl-10-hydroxycamptothecin (SN-38), an active metabolite of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11). Furthermore, isobologram analysis indicated synergistic interaction of CDDP and SN-38 only for HeLa/CDDP cells. The present study suggests that combination therapy with CDDP and CPT-11 may be potentially useful in the treatment of some patients with CDDP-resistant cancer.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Camptothecin,
http://linkedlifedata.com/resource/pubmed/chemical/Cisplatin,
http://linkedlifedata.com/resource/pubmed/chemical/Etoposide,
http://linkedlifedata.com/resource/pubmed/chemical/Glutathione,
http://linkedlifedata.com/resource/pubmed/chemical/Methionine,
http://linkedlifedata.com/resource/pubmed/chemical/buthionine,
http://linkedlifedata.com/resource/pubmed/chemical/irinotecan
|
pubmed:status |
MEDLINE
|
pubmed:month |
Sep
|
pubmed:issn |
0910-5050
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
85
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
966-71
|
pubmed:dateRevised |
2007-9-25
|
pubmed:meshHeading |
pubmed-meshheading:7961127-Camptothecin,
pubmed-meshheading:7961127-Cisplatin,
pubmed-meshheading:7961127-Drug Resistance,
pubmed-meshheading:7961127-Etoposide,
pubmed-meshheading:7961127-Glutathione,
pubmed-meshheading:7961127-HeLa Cells,
pubmed-meshheading:7961127-Humans,
pubmed-meshheading:7961127-Methionine
|
pubmed:year |
1994
|
pubmed:articleTitle |
Synergistic enhancement of cisplatin cytotoxicity by SN-38, an active metabolite of CPT-11, for cisplatin-resistant HeLa cells.
|
pubmed:affiliation |
Department of Obstetrics and Gynecology, Tottori University School of Medicine, Yonago.
|
pubmed:publicationType |
Journal Article,
In Vitro
|